Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren add-on therapy for progression of coronary atherosclerosis
2008-006447-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Aliskiren plus optimal baseline therapy with Placebo plus optimal baseline therapy (2 arms). Started Jan 2009; status: completed.
02
Drugs
aliskiren
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2008-006447-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006447-40.